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Abstract: 
The present work delineates the combinatorial approach of firstly, creation of a centralized data-set comprising signalling proteins identified on the basis of altered 
expression, such as over-expression or repression of a set of signalling protein(s) leading to the cause of the disease, which is based on published reports screened 
through Pubmed and secondly, in the in silico creation of novel lead (drug) molecules and docking of identified signalling biomarkers using such drugs to 
investigate possibility of their future application in the model systems eventually. EPAC (Exchange Protein Activated by cAMP) emerges as a signalling 
biomarker in cases studied presently. Brefeldin, the known inhibitor of EPAC, though the mechanism yet unexplored, has been the molecule used as the 
pharmacophore for creation of lead drug molecule. Various modifications have been incorporated into the pharmacophore to increase the hydrophobic interactions 
for increasing the binding efficiency of the generated lead molecule. Side-chain modifications of the pharmacophore and refinement of data through firedock upon 
docking of EPAC with the modified pharmacophore yielded best results on the bases of atomic contact energy, van der Waal and partial electrostatic interactions 
as well as additional estimations of the binding free energy. Modifications of CH3 at C15 with COOH and H at C2 with OH in brefeldin showed the best docking 
results on the basis of protein-drug interaction parameters. The present work provides a clue in rational design of EPAC inhibitors which could be developed as 
drug lead in combating CVD. 
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Background: 
Cardiovascular disease (CVD) is known as the leading cause of human deaths 
the world over. Strategies encompassing drug docking using genome and 
proteome interfaces and wet lab-based drug applications on animal models and 
cells in vitro are underway in most of the laboratories as strategies to control 
the disease. However, mortality rate of the affected human population due to 
CVD is still high. Consequently, a better management of the disease is 
required. Given the importance of cell signalling in the basic understanding of 
a pathway and its involvement in the exploration of the disease, its applicability 
in the identification of CVD hot-spots could precisely be pinpointed by 
identification of novel protein targets and creating suitable drug leads to 
modulate their expression. The disease management can be achieved better if 
there is availability of a central repository of data comprising molecules which 
are critical to the cause of such diseases. The created data-set will provide ease 
in the planning and execution of experimental strategy for systematic testing 
and prioritization of candidate molecules for drug discovery and allow in silico 
creation of better lead molecules for targeting the disease comprehensively. 
EPAC is a guanine nucleotide exchange factor catalysing exchange of GDP for 
GTP and has been pivotal in controlling a number of cellular processes through 
sensing the cAMP levels in cells involved in focal adhesion formation, 
migration, apoptosis and axon growth and guidance [1, 2, 3]. The factors 
contributing to abnormal cAMP levels in the cells range from hyperactive 
receptors (metabotropic receptors) [4], aberrant expression of polycystin, which 
is crucial in the cause of autosomal dominant polycystic kidney disease 
(ADPKD)  [5] and various cyclic nucleotide phosphodiesterases (PDEs), of 
which 11 families are known and which catalyze the hydrolysis of cAMP [6]. 
 
In various Pubmed based data analysis criteria through a bioinformatic 
approach carried out presently, EPAC emerged out to be a biomarker in some 
CVD cases of myrocardial hypertrophy [7, 8] and hence had been the target for 
lead molecule generation. Brefeldin, initially isolated as an anti-viral antibiotic 
and a known drug for activating a GTPase of a GEF called Arf1p, which is 
involved in the formation of transport vesicles by recruiting coat proteins to 
intracellular membranes, was employed for generation of the pharmacophore. BIOINFORMATION  open access 
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Materials & Methodology: 
There is a vast body of literature available in PubMed on the given subject. 
Refinement in the searches were made by specific keywords, which make the 
information more relevant to our requirement (Figure 1). Data-sets comprising 
Molecular Interaction, Receptor(s) (membrane-bound) involved, Critical 
Interaction leading to over-expression or repression and the PubMed reference 
link (PMID) were created on the excel sheet. The biomarker was identified 
using the criteria of catalysed molecule and its case specific occurrence 
manner. Pharmacophore was generated from the reported drugs for the 
identified biomarker and side chain modifications were made based on logistics 
worked out on the basis of the existing interactions of the natural ligand for the 
biomarker (protein). For docking and refinement, online free wares such as 
Patchdock  [9] and Firedock [10, 11, 12] were used, respectively. For 
highlighting interactions, Ligplot [13] was used as a tool. 
 
 
Figure 1: Data curation protocol for cataloguing the signaling pathway 
molecules  
 
 
Figure 2: The criteria adopted for curating the signalling molecules. 
 
Results and Discussion: 
Data Annotation criteria adopted for cataloguing the biomarker 
molecules:  
A search in the Pubmed through the keyword “Signal transduction and 
Cardiovascular disease” typically fetches over 13000 references, of which 
around 4500 belongs to the review category, while the rest belongs to the 
research articles. A careful reading of majority of such articles yielded data on 
the above mentioned aspects. Figure 1 & 2 highlight the criteria adopted for 
the purpose. All the molecules participating in the signalling network were 
annotated as Molecular Interaction and the molecules associated directly or 
indirectly with an effector for upregulation or downregulation of the effector 
are considered as critical interaction. Of the critical interaction, protein-protein 
interactions at the cellular and nuclear levels were annotated separately 
considering the fact that they were crucial in the up-regulation or down-
regulation of genes.  
 
Data-set of proteins involved and their downstream effects: 
There are over 500 proteins annotated to be involved in molecular interactions 
in CVD pathways. Of these, 320 protein categories are of G-protein coupled 
receptor (GPCR) mediated responses, while rest belongs to the category of 
receptor tyrosine kinase (RTK) mediated and other or indirect receptor-
mediated effects. The GPCR-mediated response has been able to culminate its 
effect primarily on GPCR-response Kinase (GRK) in isoform-specific manner, 
NFAT and EPAC in the cell line based studies in CVD cases. The RTK 
mediated response effects in activation of NFkB primarily for CVD cases 
considered presently. The critical module of protein-protein interaction in the 
present case envisage that kinase-kinase and kinase-transcription factor 
(Elk/PAK-NFkB) are important interactions delineating the pathway of 
signalling process, which leads to activation of the response genes. 
 
Protein-Protein Interaction data-set:  
A total of 250 interactions of proteins out of 500 proteins annotated to be 
involved in CVD pathways. The protein-protein interactions were divided into 
two modules, such as kinase-kinase/adaptor/GEF interactions and kinase-
transcription factor interactions (Figure 2). Of these, there were more than 200 
interactions, which belonged to kinase-kinase/adaptor/GEF category and 30 
interactions were of kinase-transcription factor category as regards CVD 
pathways. Of these interactions, the modules considered critical in the sense 
that they controlled the pathway execution in a specific manner and the 
alteration in their expression was mainly responsible for cause of CVD.  
 
Protein-transcription factor data-set:  
Of the total protein-protein interactions mentioned above, 30 interactions 
belonged to protein-transcription factor category for CVD. In the CVD related 
signalling pathway, 12 interactions were mediated upon GPCR activation, 
while 18 interactions were the outcome of RTK activation.  
 
 
Figure 3: PDB ID: 3CF6, Epac protein (Shown in Green is Epac2) is activated 
by binding of the second messenger cAMP (Shown in Red,It is an analogue of 
cAMP) and then act as guanine nucleotide exchange factors for Rap proteins 
(Shown in Blue,It is Rap1B) [21]. 
 
Drug Docking of the Marker Molecule:  
In totality 3 molecules emerged as markers of CVD as per the criteria 
envisaged in the present analysis, which are EPAC, GRK-2 & GRK-5 as well 
as NFkB. Drug Docking using Patchdock [9] to identify the lead drug 
molecules were performed with EPAC (3CF6) presently, which is a known 
guanine exchange factor activated by cAMP. Brefeldin A, the currently known 
natural inhibitor of EPAC [14] was used as the template for generation of lead 
molecule. There is binding of cAMP in the natural EPAC molecule (Figure 3). 
The topology of 3 CF6 using PDBsum revealed the residues interacting with 
SP12 E (a natural ligand, cAMP for 3CF6, Fig not shown) and the interactions 
were refined using Ligplot [13]. The interacting atoms or groups available in 
the binding sites of cAMP, the natural ligand for EPAC, were chosen as 
reference for incorporating similar modifications in brefeldin (the chosen 
ligand for the present work) to increase the hydrophobic interactions and 
increase the binding efficiency of the generated brefeldin lead molecule (BR2). 
Of the various interactions occurring in the docked interface and scored 
through Ligplot [13], hydrophobic interactions were prevalent, revealing the 
stability of the interaction. In all, 12 different modifications were made and 
BR2 molecule generated by replacement of -CH3 at C15 and -H at C2 with – 
COOH and –OH, respectively yielded H- bond interactions between BR2 and 
Ala 407 (E), which in turn induced additional H-bond formation between –OH BIOINFORMATION  open access 
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at C1 and C7 and Ala 416 and Cys 395, respectively. These interactions induce 
further stability in the complex by improved hydrophobic interactions (Figure 
4A-D). 
 
 
Figure 4(A): Structure of unmodified brefeldin; 4(B): Interactions between 
unmodified Brefeldin and residues of Chain E of EPAC. Fewer groups are 
found to be involved in hydrophobic interaction and no H-bond is observed; 
4(C): Structure of modified brefeldin (BR2); 4(D): The interactions between 
BR2 (modified brefeldin) and residues of Chain E of EPAC are shown. Of the 
12 different modifications involving C2, C10 and C15 of brefeldin 
pharmacophore, the replacement of -CH3 at C15 and -H at C2 with – COOH 
and –OH, respectively yielded H- bond interactions between BR2 and Ala 407 
(E) [highlighted as boxed area], which in turn induced additional H-bond 
formation between –OH at C1 and C7 and Ala 416 and Cys 395, respectively. 
These interactions induce further stability in the complex by improved 
hydrophobic interactions. 
 
Molecular modelling approaches in designing and devising new drug leads 
have been a recent approach in addressing the disease problems. Diseases such 
as cancer [15], gout [16], cardiac damage [17] and various others [18, 19] have 
been the subject of studies on the lines of the present work. An emerging trend 
is thus approaching towards dealing with the disease bioinformatically on the 
first hand basis because of the ease and sufficiency of the technology involved 
in data annotation process. However, the biomarkers identified and the drug 
leads created need to be validated through targeted approaches by the support 
of systems medicine approach [20]. 
 
Conclusion: 
EPAC is the signalling biomarker identified in cardiovascular (CVD) cases 
through a bioinformatic approach undertaken presently and drug leads were 
generated using existing online softwares, which could be useful in synthesis of 
chemical drugs for further analysis in controlling the disease. It is assumed that 
the present work would contribute towards augmenting the repertoire of 
knowledge available on formulations of drug for combating CVD. 
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